Bioventix entered this full year update on a strong run, with the stock up more than 30% over the past three months and trading at £19.90 at last close. The long term pitch is clear: a high margin antibody specialist with rich cash generation and an income story that attracts yield focused investors.
Today's FY 2026 numbers keep that profitability story in focus. Net profit margin sits close to 59% and basic earnings per share reach about £1.46 over the trailing twelve months. The share price reaction now becomes a verdict on whether that rich margin profile outweighs concerns about the current dividend coverage.
Love Bioventix's rich margins but uneasy about the dividend coverage question and the concentration risk around a single income stream? Take a look at our curated list of higher quality balance sheet and fundamentals stocks in the list of solid balance sheet and fundamentals stocks (10 results)
FY 2026 Earnings Summary
-
Revenue (FY 2026 vs FY 2025 TTM):£12.97m vs. £13.12m (broadly stable on a trailing twelve month basis)
-
Net Income (FY 2026 vs FY 2025 TTM):£7.61m vs. £7.58m (around 0.4% higher on trailing earnings)
-
Basic EPS (FY 2026 vs FY 2025 TTM):£1.46 vs. £1.45 (around 0.4% higher for shareholders over the year)
-
Net Profit Margin (FY 2026 vs FY 2025 TTM):58.7% vs. 57.8% (slightly firmer profitability for Bioventix)
Earnings tell part of the story, but investors who care about what they are actually paying for often focus on the cash that Bioventix turns those profits into over time. Look through Bioventix's cash flows alone and the stock could be a meaningful 29% undervalued .
Bioventix margins keep the quality story intact
For anyone backing Bioventix as a high quality cash generator, the latest earnings keep the storyline intact. Revenue and net income are broadly steady on a trailing basis, with net profit margin close to 59%. That kind of profitability is rare in diagnostics suppliers and suggests the core antibody franchise is still doing the heavy lifting. The slight uplift in margin versus the prior twelve months hints that pricing, mix, or cost discipline is not slipping, which supports the idea of a resilient, high return business rather than a one off windfall.
Dividend strain and concentration risks still visible
The other side of the Bioventix narrative has not gone away. Income investors focus on dividend coverage and the reliance on a concentrated royalty stream. These full year figures do not show a clear step change in revenue or earnings that would ease those concerns. With top line essentially flat and profit edging only fractionally higher, distributions still lean heavily on an already efficient model. That keeps the question open about how comfortably the current payout can be maintained if a key diagnostic customer or assay ever stumbles.
After a 7.54% yield that is not well covered by free cash flow, it is fair to ask what else might be lurking beneath the surface. Review our structured risk analysis for Bioventix which shows 1 important warning sign
Hunt For Stronger Cash Stories
Bioventix shows how a rich profit pool can still leave investors weighing customer concentration and dividend funding. The real opportunity is finding stocks that could be undervalued before the market corrects them.
-
Company 1 - 34% below our estimate - integrate membership, recommerce and logistics to reduce service costs and raise reuse volumes.
-
Company 2 - 23% below our estimate - turn a long-cycle order book in munitions, vehicles and space into higher production as digital factories scale.
-
Company 3 - 40% below our estimate - reallocate capital toward private credit and equity funds so partnerships and co-investments broaden fee-earning assets.
Three companies from the same screener. Open every one of the 10 undervalued companies on it →
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include BVXP.aim .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
